Renizgamglogene autogedtemcel

雷尼基奥杰干赛

Report date: 2025/07/30 13:53:44

Base Information

Drug NameRenizgamglogene autogedtemcel

Drug Alias NameHBB CRISPR/Cas9 ex vivo gene therapyex vivo HBB-edited hematopoietic stem cell therapyex vivo CRISPR/Cas9/HBB stem cell-based gene therapyEx vivo gene edited cell medicine (Editas Medicine)Reni-cel +[6]

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derived +[4]

Mechanisms of ActionHemoglobin subunit gamma-1 gene transferenceHemoglobin subunit gamma-2 gene transferenceStem cell replacements

TargetsHemoglobin subunit gamma-1Hemoglobin subunit gamma-2

Therapy Area/IndicationsHemoglobinopathiesbeta-ThalassemiaAnemia, Sickle Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesEditas Medicine Inc

China Registration ClassN/A

Develop Information

Active CompaniesEditas Medicine Inc

Inactive CompaniesN/A

Active IndicationsHemoglobinopathiesbeta-ThalassemiaAnemia, Sickle Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A